<?xml version="1.0" encoding="UTF-8"?>
<p id="Par68">4. Previous history of COVID-19 in HIV/TB co-infection: This group of cases should be treated as HIV/TB co-infection as described in different national guidelines. Therefore, emphasis should be put on the risk of severe lung fibrosis that may induce MDR-TB or XDR-TB. Ongoing trials are evaluating the safety and effectiveness of antifibrotic therapy in COVID-19 severe and critical patients [
 <xref ref-type="bibr" rid="CR46">46</xref>]. This could be beneficial in COVID-19-HIV and TB co-infected cases due to their synergic roles in inducing pulmonary fibrosis.
</p>
